about
Biomedical applications of functionalized hollow mesoporous silica nanoparticles: focusing on molecular imagingSurface engineering of graphene-based nanomaterials for biomedical applicationsDynamic Positron Emission Tomography Imaging of Renal Clearable Gold Nanoparticles.Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacyNon-invasive multimodal functional imaging of the intestine with frozen micellar naphthalocyaninesTheranostic unimolecular micelles based on brush-shaped amphiphilic block copolymers for tumor-targeted drug delivery and positron emission tomography imagingGeneration and screening of monoclonal antibodies for immunoPET imaging of IGF1R in prostate cancer.VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide in vivo.VEGF₁₂₁-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system.PET of follicle-stimulating hormone receptor: broad applicability to cancer imagingIn Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine.PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor.PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment.ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragmentComparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal ModelsFeSe2-Decorated Bi2Se3 Nanosheets Fabricated via Cation Exchange for Chelator-Free 64Cu-labeling and Multimodal Image-Guided Photothermal-Radiation Therapy.Long circulating reduced graphene oxide-iron oxide nanoparticles for efficient tumor targeting and multimodality imaging.Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles.In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles.Chelator-free synthesis of a dual-modality PET/MRI agent.Engineering Intrinsically Zirconium-89 Radiolabeled Self-Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies.A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer.Radiolabeled, Antibody-Conjugated Manganese Oxide Nanoparticles for Tumor Vasculature Targeted Positron Emission Tomography and Magnetic Resonance Imaging.Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.Chelator-Free Radiolabeling of Nanographene: Breaking the Stereotype of Chelation.General synthesis of silica-based yolk/shell hybrid nanomaterials and tumor vasculature targetingIntegrin αβ-targeted [Cu]CuS Nanoparticles for PET/CT Imaging and Photothermal Ablation TherapyIn Vivo Tumor-Targeted Dual-Modality PET/Optical Imaging with a Yolk/Shell-Structured Silica NanosystemMonoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral GrowthIntrinsically Zirconium-89-Labeled Manganese Oxide Nanoparticles for In Vivo Dual-Modality Positron Emission Tomography and Magnetic Resonance ImagingCopper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor RetentionRecent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer
P50
Q26827998-990D263C-6F4F-432E-8AEE-370CD6975397Q26853158-D74DF241-D70E-47D4-9755-31764E9C2E35Q30759992-21FF6173-ABAA-4BE1-8EF1-24B391F2F7F6Q33687218-2DAC4510-0E43-4038-9A7B-F6021B2A209CQ34034249-26D7FB08-1CD9-44D8-A22A-3037C93C4502Q34178035-7A86CFE3-6B5C-41AD-9D48-82413ABBCD6EQ34293602-2B869B71-90B7-4703-A6ED-0020D628E9ADQ34650180-900D974B-2DFE-498C-9B32-1D6360B8624EQ34674541-21C228FB-E979-4D4E-AEA3-346929826361Q35153873-31E9343F-D3A8-4DF5-A973-A909BFAF9625Q35554806-7DA9D51D-F96B-42AB-AD5E-7B032B06F752Q35562996-745D860D-417B-46BD-A1DD-BFEAC051796EQ35674858-47E68984-3932-4805-925E-7F700ABBD876Q35788352-0951AB89-9CD7-4AA8-8459-7CFB12B8AFDEQ36436914-BD5BCFAA-CA40-4271-8BBE-9069CDDBA55DQ36818486-DCED52CD-960F-4166-BD1E-DBB2BFB3FACCQ37033916-CF94DC8B-7744-4FB2-8538-5C049D132A4EQ37202881-75BD3502-AB5D-4EB6-86E5-7B72CC9BCBBCQ37327759-26F051FD-C079-4E72-AA3D-24BC7FD0B64FQ37374640-5516E9EF-03EC-4411-9770-5E63D9A51116Q37404653-CED32AE8-32B6-4D55-B9A3-70626E2B02B4Q38744668-55937A52-C781-484F-AC26-6C8FCCAA17B3Q42385426-2B62E2B6-6D8F-4633-A14A-54451A9797D7Q47447811-C785E6F6-C8A4-4551-89C3-EF5FAE77FCB0Q49919933-D0F76C0C-8543-4DD0-A287-EEA8A344510DQ54530868-FFFACA17-2684-4A21-8902-B1440C594D75Q58560988-FB3B0482-D3A2-4B9D-8BF6-81F8E23F7C6AQ58575495-EFF83171-94CC-4911-A67B-CFCE62A9ECC3Q58582293-4DC2D0E1-2F8C-41E6-8A0A-3F0B2DB3987AQ64245224-D554C86A-C329-4C7E-B4C8-C4DD45A2025CQ89043114-9E31A0DB-C403-4E79-BC51-4F7DEDF631A9Q90328483-E533E0F0-DF1F-4F92-9FC4-B1B44D4D76B4Q91851340-97EE1FC2-3C08-4FA7-8B37-ECDD11B8CE8E
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Sixiang Shi
@en
Sixiang Shi
@nl
type
label
Sixiang Shi
@en
Sixiang Shi
@nl
prefLabel
Sixiang Shi
@en
Sixiang Shi
@nl
P31
P496
0000-0002-8354-7620